Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO
Rhea-AI Filing Summary
Kazia Therapeutics Limited has appointed Dr. Sudha Rao as Chief Scientific Officer under a new employment agreement. Effective April 13, 2026, she will serve part-time, three days per week, with an annual base salary of AUD$325,000 and a target annual bonus equal to 40% of base salary.
The agreement includes options to acquire 250,000 American Depositary Shares, with one-third vesting at commencement and the remainder vesting in equal tranches on the first and second anniversaries, subject to board approval. Dr. Rao will continue her role at QIMR Berghofer Medical Research Institute while leading Kazia’s scientific and R&D strategy.
Positive
- None.
Negative
- None.
Key Figures
Base salary: AUD$325,000 per year
Target bonus: 40% of base salary
Equity grant: 250,000 ADS options
+4 more
7 metrics
Base salary
AUD$325,000 per year
Annual base salary for CSO role under Employment Agreement
Target bonus
40% of base salary
Annual performance bonus target for CSO
Equity grant
250,000 ADS options
Stock options for Chief Scientific Officer, subject to board approval
Work schedule
3 days per week
Part-time basis for Chief Scientific Officer role
Agreement date
April 10, 2026
Date Employment Agreement with Dr. Sudha Rao was entered into
Commencement date
April 13, 2026
Effective date for Dr. Rao’s service as Chief Scientific Officer
Press release date
April 15, 2026
Date of press release announcing CSO appointment
Key Terms
American Depositary Shares, performance bonus, Orphan Drug Designation, Fast Track Designation, +2 more
6 terms
performance bonus financial
"eligible to receive an annual performance bonus with a target of 40% of her base salary"
Orphan Drug Designation regulatory
"Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Paxalisib was granted Orphan Drug Designation for glioblastoma... and Fast Track Designation (FTD) for glioblastoma"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Rare Pediatric Disease Designation regulatory
"paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA"
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.
epigenetic therapeutics medical
"has advanced first-in-class epigenetic therapeutics from discovery through IND-enabling studies"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive change did Kazia Therapeutics (KZIA) announce in this 6-K?
Kazia Therapeutics appointed Dr. Sudha Rao as Chief Scientific Officer. She will lead research and development and platform strategy while serving part-time and continuing her role at QIMR Berghofer Medical Research Institute, strengthening the company’s scientific leadership in oncology.
What are the key terms of Dr. Sudha Rao’s employment with Kazia Therapeutics (KZIA)?
Dr. Rao will serve as part-time Chief Scientific Officer three days per week with an annual base salary of AUD$325,000 and an annual performance bonus targeted at 40% of base salary, subject to performance objectives set by Kazia’s board of directors.
What equity compensation will Dr. Sudha Rao receive from Kazia Therapeutics (KZIA)?
Dr. Rao’s agreement includes options to acquire 250,000 American Depositary Shares of Kazia, subject to board approval. One-third vests at employment commencement, and the remaining two-thirds vest in two equal annual installments on the first and second anniversaries of her start date.
Can Kazia Therapeutics (KZIA) Chief Scientific Officer Dr. Sudha Rao hold other roles?
Yes. The employment agreement explicitly permits Dr. Sudha Rao to maintain concurrent employment with QIMR Berghofer Medical Research Institute while serving as part-time Chief Scientific Officer at Kazia, allowing her to continue leading her academic research laboratory.
How does Kazia Therapeutics (KZIA) use this 6-K in its Form F-3 registrations?
Kazia incorporates by reference the information in this report, including the employment agreement and press release, into its Form F-3 registration statements, excluding quotes from its CEO and certain prior exhibit materials related to a separate director departure disclosure.